4RD logo

MaaT Pharma DB:4RD Stock Report

Last Price

€7.70

Market Cap

€111.1m

7D

3.5%

1Y

22.2%

Updated

11 Dec, 2024

Data

Company Financials +

4RD Stock Overview

A clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. More details

4RD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MaaT Pharma SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MaaT Pharma
Historical stock prices
Current Share Price€7.70
52 Week High€9.92
52 Week Low€5.80
Beta0.18
11 Month Change3.49%
3 Month Change12.57%
1 Year Change22.22%
33 Year Change-41.89%
5 Year Changen/a
Change since IPO-40.08%

Recent News & Updates

Recent updates

Shareholder Returns

4RDDE BiotechsDE Market
7D3.5%2.4%1.7%
1Y22.2%-12.1%9.6%

Return vs Industry: 4RD exceeded the German Biotechs industry which returned -12.1% over the past year.

Return vs Market: 4RD exceeded the German Market which returned 9.6% over the past year.

Price Volatility

Is 4RD's price volatile compared to industry and market?
4RD volatility
4RD Average Weekly Movement4.5%
Biotechs Industry Average Movement6.7%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 4RD has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 4RD's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201454Herve Affagardwww.maatpharma.com

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.

MaaT Pharma SA Fundamentals Summary

How do MaaT Pharma's earnings and revenue compare to its market cap?
4RD fundamental statistics
Market cap€111.07m
Earnings (TTM)-€24.14m
Revenue (TTM)€2.57m

43.2x

P/S Ratio

-4.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4RD income statement (TTM)
Revenue€2.57m
Cost of Revenue€1.13m
Gross Profit€1.44m
Other Expenses€25.58m
Earnings-€24.14m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.73
Gross Margin56.01%
Net Profit Margin-938.86%
Debt/Equity Ratio45.0%

How did 4RD perform over the long term?

See historical performance and comparison